Calidi Biotherapeutics, Inc. Increase (Decrease) in Prepaid Expense
Calidi Biotherapeutics, Inc. (CLDI) reported Increase (Decrease) in Prepaid Expense of -$182.17 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2023-08-21
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2023-06-30 was -$60.42K.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2023-03-31 was -$121.74K.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2022-12-31 was -$132.24K.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2022-09-30 was -$68.71K, a 108.75% decline year-over-year.
- Calidi Biotherapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2022 was -$394.94K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$60.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$182.17K 10-Q · filed 2023-08-21 | -$314.41K derived: sum of 3 quarters · filed 2023-08-21 | -$383.12K derived: sum of 4 quarters · filed 2023-08-21 |
| 2023-03-31 | -$121.74K 10-Q · filed 2023-05-15 | -$253.98K derived: sum of 2 quarters · filed 2023-05-15 | -$322.69K derived: sum of 3 quarters · filed 2023-05-15 | -$428.81K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-12-31 | -$132.24K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$200.95K derived: sum of 2 quarters · filed 2023-03-31 | -$307.06K derived: sum of 3 quarters · filed 2023-08-21 | -$394.94K 10-K · filed 2023-03-31 |
| 2022-09-30 | -$68.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$174.82K derived: sum of 2 quarters · filed 2023-08-21 | -$262.70K 10-Q · filed 2022-11-14 | -$368.45K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-06-30 | -$106.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$193.99K 10-Q · filed 2023-08-21 | -$299.74K derived: sum of 3 quarters · filed 2023-08-21 | $485.36K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | -$87.88K 10-Q · filed 2023-05-15 | -$193.62K derived: sum of 2 quarters · filed 2023-05-15 | $591.47K derived: sum of 3 quarters · filed 2023-05-15 | $613.97K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$105.74K derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $679.35K derived: sum of 2 quarters · filed 2023-03-31 | $701.85K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $785.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $807.60K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $22.50K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |